Acesso livre
Acesso livre

Vacinas

[Preprint] Em estudo randomizado com 29.949 participantes, a vacina Novavax demonstrou alta eficácia geral (> 90%) na prevenção de Covid-19, e todos os casos moderados a graves ocorreram no grupo placebo.

14 Out, 2021 | 10:55h

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico – medRxiv

Comentário: Novel vaccine demonstrates high efficacy for prevention of COVID-19 – News Medical

Contéudos relacionados:

RCT: Novavax vaccine conferred 89.7% protection against symptomatic SARS-CoV-2 infection and 100% protection against hospitalizations or deaths.

Opinion | The mRNA vaccines are extraordinary, but Novavax is even better.

(Press release – not published yet) Novavax COVID-19 vaccine demonstrates 90% overall efficacy and 100% protection against moderate and severe disease.

RCT: Novavax vaccine is 49.4% effective against B.1.351 SARS-CoV-2 variant.

[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant

New COVID-19 vaccines: here’s how the promising Novavax and Johnson & Johnson jabs work

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

 

Comentário no Twitter

 

Como o Covax falhou em sua promessa de vacinar o mundo – “Covax, descrito como ‘ingenuamente ambicioso’ por um especialista, contribuiu com apenas 5% de todas as vacinas administradas globalmente.”

14 Out, 2021 | 10:49h

How Covax failed on its promise to vaccinate the world – The Bureau of Investigative Journalism

Conteúdos relacionados:

Perspective | A beautiful idea: how COVAX has fallen short.

WHO Launches Strategy to Achieve Global Covid-19 Vaccination by mid-2022.

WHO special envoys: To beat Covid, there’s a simple lesson – no one’s safe until everyone’s safe.

Joint COVAX Statement on the Equal Recognition of Vaccines – COVAX urges all government authorities to recognize as fully vaccinated all people who have received COVID-19 vaccines that have been deemed safe and effective by WHO.

WHO COVAX Joint Statement: Call to action to equip COVAX to deliver 2 billion doses in 2021.

Covax: How will Covid vaccines be shared around the world?

OMS recomenda a aplicação da 3ª dose da vacina contra COVID em grupos de mais alto risco.

13 Out, 2021 | 13:43h

WHO advisers recommend 3rd COVID vaccine dose for highest-risk groups – CIDRAP

Ver também: WHO advises additional COVID shot for immunocompromised people – Reuters

Estudo nacional na Suécia mostra ligação entre vacinação contra COVID e redução na transmissão domiciliar.

13 Out, 2021 | 12:53h

Comunicado de imprensa: Nationwide study shows link between COVID vaccination and reduced household transmission – Umea University

Estudo original: Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members – JAMA Internal Medicine

Conteúdos relacionados:

Review | Prevention of host-to-host transmission by SARS-CoV-2 vaccines.

Study ties COVID vaccines to lower transmission rates.

Effect of Vaccination on Household Transmission of SARS-CoV-2 in England – “the likelihood of household transmission was approximately 40 to 50% lower in households of index patients who had been vaccinated 21 days or more before testing positive than in households of unvaccinated index patients”.

Study in England showed one dose of COVID-19 vaccine can cut household transmission by up to half – This protection is on top of the reduced risk of a vaccinated person developing symptomatic infection, which is around 60 to 65% after the first dose

Covid-19 vaccination prevents transmission from vaccinated to unvaccinated household members.

Bioética | O “problema do bonde” e a vacinação de jovens contra a COVID-19.

12 Out, 2021 | 11:18h

The Trolley Problem and Vaccinating Young People Against COVID-19 – Science-Based Medicine

É muito baixo o risco de inflamação cardíaca após vacina da Pfizer contra COVID.

12 Out, 2021 | 11:15h

Heart-inflammation risk from Pfizer COVID vaccine is very low – Nature

Estudos originais:

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Estudo mostra risco aumentado de síndrome de Guillain-Barré após vacina da J&J; a razão de taxas foi de 4,18 para uma janela de 42 dias.

8 Out, 2021 | 12:27h

Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021 – JAMA

 

Comentário no Twitter

 

Dados de mundo real mostram reatogenicidade aumentada em adultos após vacinação heteróloga em comparação à homóloga contra COVID-19.

8 Out, 2021 | 12:25h

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance

Conteúdos relacionados:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Comentário no Twitter

 

Estudo observacional no Catar mostrou que a efetividade da vacina da Pfizer contra qualquer infecção por SARS-CoV-2 caiu para 20% entre o 5º e o 7º mês após a segunda dose, mas a efetividade contra Covid-19 grave permaneceu alta.

8 Out, 2021 | 12:04h

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar – New England Journal of Medicine

Conteúdo relacionado: Cohort study: Pfizer vaccine effectiveness against any infections declined from 88% during the first month after full vaccination to 47% after 5 months. Vaccine effectiveness against hospital admissions remained high; 87% within 1 month, and 88% at 5 months after full vaccination, with no significant waning.

 

Comentário no Twitter

 

Amplo estudo de coorte com mais de 2.5 milhões de indivíduos mostrou que a incidência de miocardite após a vacina da Pfizer foi de 2,13 casos por 100.000 pessoas.

8 Out, 2021 | 12:02h

Myocarditis after Covid-19 Vaccination in a Large Health Care Organization – New England Journal of Medicine

Comentário: Studies Highlight Rarity of Myocarditis With mRNA COVID-19 Vaccines – TCTMD

Estudo relacionado: Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel – New England Journal of Medicine

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.